Cargando…

Correlation of [(18)F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma

OBJECTIVE: To analyze the pattern of failure in relation to pre-treatment [(18)F] FDG-PET/CT uptake in head and neck squamous cell carcinoma (HNSCC) patients treated with definitive radio-chemotherapy (RT-CHT). METHODS AND MATERIALS: From 2012 to 2016, 87 HNSCC patients treated with definitive RT-CH...

Descripción completa

Detalles Bibliográficos
Autores principales: Pisani, C., Vigna, L., Mastroleo, F., Loi, G., Amisano, V., Masini, L., Deantonio, L., Aluffi Valletti, P., Sacchetti, G., Krengli, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981918/
https://www.ncbi.nlm.nih.gov/pubmed/33743759
http://dx.doi.org/10.1186/s13014-021-01787-5
_version_ 1783667611831107584
author Pisani, C.
Vigna, L.
Mastroleo, F.
Loi, G.
Amisano, V.
Masini, L.
Deantonio, L.
Aluffi Valletti, P.
Sacchetti, G.
Krengli, M.
author_facet Pisani, C.
Vigna, L.
Mastroleo, F.
Loi, G.
Amisano, V.
Masini, L.
Deantonio, L.
Aluffi Valletti, P.
Sacchetti, G.
Krengli, M.
author_sort Pisani, C.
collection PubMed
description OBJECTIVE: To analyze the pattern of failure in relation to pre-treatment [(18)F] FDG-PET/CT uptake in head and neck squamous cell carcinoma (HNSCC) patients treated with definitive radio-chemotherapy (RT-CHT). METHODS AND MATERIALS: From 2012 to 2016, 87 HNSCC patients treated with definitive RT-CHT, with intensity modulated radiation therapy with simultaneous integrated boost, underwent pre-treatment [(18)F] FDG-PET/CT (PET(pre)), and MRI/CT for radiotherapy (RT) planning purposes. Patients with local recurrence, received [(18)F] FDG-PET/CT, (PET(rec)) at the time of the discovery of recurrence. In these patients, the metabolic target volume (MTV), MTV(pre) and MTV(rec) were segmented on PET images by means of an adaptive thresholding algorithm. The overlapping volume between MTV(pre) and MTV(rec) (MTV(pre&rec)) was generated and the dose coverage of MTV(rec) and MTV(pre&rec) was checked on the planning CT using the D99 and D95 dose metrics. The recurrent volume was defined as: ‘‘In-Field (IF)’’, “Marginal recurrence” or ‘‘Out-of-Field (OF)’’ if D95 was respectively equal or higher than 95%, D95 was between 95 and 20% or the D95 was less than 20% of prescribed dose. RESULTS: We found 10/87 patients (11.5%) who had recurrence at primary site. Mean MTV(pre) was 12.2 cc (4.6–28.9 cc), while the mean MTV(rec) was 4.3 cc (1.1–12.7 cc). Two recurrences resulted 100% inside MTV(pre), 4 recurrences were mostly inside (61–91%) and 4 recurrences were marginal to MTV(pre) (1–33%). At dosimetric analysis, five recurrences (50%) were IF, 4 (40%) marginal and one (10%) OF. The mean D99 of the overlapping volumes MTV(pre&rec) was 68.1 Gy (66.5–69.2 Gy), considering a prescription dose of 70 Gy to the planning target volume (PTV). CONCLUSION: Our study shows that the recurrence may originate from the volume with the highest FDG-signal. Tumor relapse in the high-dose volume support the hypothesis that an intensification of the dose on these volumes could be further assessed to prevent local relapse.
format Online
Article
Text
id pubmed-7981918
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79819182021-03-22 Correlation of [(18)F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma Pisani, C. Vigna, L. Mastroleo, F. Loi, G. Amisano, V. Masini, L. Deantonio, L. Aluffi Valletti, P. Sacchetti, G. Krengli, M. Radiat Oncol Research OBJECTIVE: To analyze the pattern of failure in relation to pre-treatment [(18)F] FDG-PET/CT uptake in head and neck squamous cell carcinoma (HNSCC) patients treated with definitive radio-chemotherapy (RT-CHT). METHODS AND MATERIALS: From 2012 to 2016, 87 HNSCC patients treated with definitive RT-CHT, with intensity modulated radiation therapy with simultaneous integrated boost, underwent pre-treatment [(18)F] FDG-PET/CT (PET(pre)), and MRI/CT for radiotherapy (RT) planning purposes. Patients with local recurrence, received [(18)F] FDG-PET/CT, (PET(rec)) at the time of the discovery of recurrence. In these patients, the metabolic target volume (MTV), MTV(pre) and MTV(rec) were segmented on PET images by means of an adaptive thresholding algorithm. The overlapping volume between MTV(pre) and MTV(rec) (MTV(pre&rec)) was generated and the dose coverage of MTV(rec) and MTV(pre&rec) was checked on the planning CT using the D99 and D95 dose metrics. The recurrent volume was defined as: ‘‘In-Field (IF)’’, “Marginal recurrence” or ‘‘Out-of-Field (OF)’’ if D95 was respectively equal or higher than 95%, D95 was between 95 and 20% or the D95 was less than 20% of prescribed dose. RESULTS: We found 10/87 patients (11.5%) who had recurrence at primary site. Mean MTV(pre) was 12.2 cc (4.6–28.9 cc), while the mean MTV(rec) was 4.3 cc (1.1–12.7 cc). Two recurrences resulted 100% inside MTV(pre), 4 recurrences were mostly inside (61–91%) and 4 recurrences were marginal to MTV(pre) (1–33%). At dosimetric analysis, five recurrences (50%) were IF, 4 (40%) marginal and one (10%) OF. The mean D99 of the overlapping volumes MTV(pre&rec) was 68.1 Gy (66.5–69.2 Gy), considering a prescription dose of 70 Gy to the planning target volume (PTV). CONCLUSION: Our study shows that the recurrence may originate from the volume with the highest FDG-signal. Tumor relapse in the high-dose volume support the hypothesis that an intensification of the dose on these volumes could be further assessed to prevent local relapse. BioMed Central 2021-03-21 /pmc/articles/PMC7981918/ /pubmed/33743759 http://dx.doi.org/10.1186/s13014-021-01787-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Pisani, C.
Vigna, L.
Mastroleo, F.
Loi, G.
Amisano, V.
Masini, L.
Deantonio, L.
Aluffi Valletti, P.
Sacchetti, G.
Krengli, M.
Correlation of [(18)F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma
title Correlation of [(18)F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma
title_full Correlation of [(18)F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma
title_fullStr Correlation of [(18)F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma
title_full_unstemmed Correlation of [(18)F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma
title_short Correlation of [(18)F] FDG-PET/CT with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma
title_sort correlation of [(18)f] fdg-pet/ct with dosimetry data: recurrence pattern after radiotherapy for head and neck carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981918/
https://www.ncbi.nlm.nih.gov/pubmed/33743759
http://dx.doi.org/10.1186/s13014-021-01787-5
work_keys_str_mv AT pisanic correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma
AT vignal correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma
AT mastroleof correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma
AT loig correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma
AT amisanov correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma
AT masinil correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma
AT deantoniol correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma
AT aluffivallettip correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma
AT sacchettig correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma
AT krenglim correlationof18ffdgpetctwithdosimetrydatarecurrencepatternafterradiotherapyforheadandneckcarcinoma